Argenx awarded EUR2.5m VLAIO grant to research novel therapeutic antibodies.
M2 EQUITYBITES-March 16, 2018-Argenx awarded EUR2.5m VLAIO grant to research novel therapeutic antibodies
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Flanders Innovation and Entrepreneurship (VLAIO) has awarded Argenx (EBR: ARGX) a grant of EUR2.5m, the company announced on Friday.
The funding will be used to research the role and therapeutic potential of proteins involved in regulating localised release of transforming growth factor beta.
VLAIO's subsidy was granted to Argenx through its Innovative Access Programme (IAP) as funding of research around selective SIMPLE Antibody inhibition of TGF-beta for potential therapeutic use in immuno-oncology.
Argenx's proprietary SIMPLE Antibody discovery platform enables the discovery of antibodies that target novel and complex disease targets. The technology has already generated antibody leads with attributes that are unattainable using current platforms.
The company believes the IAP will enable it to progress to mature a unique and sustainable pipeline, allowing it to bring cutting edge antibody discovery technologies to the centre of novel target research.
Vice president of External Research at Argenx, Michael Saunders, explained that TGF-beta plays an important role in immunosuppression and, as a result, the company sees "inhibition of this target as an important therapeutic goal in immuno-oncology."
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 16, 2018|
|Previous Article:||Stantec announces receipt of concept design contract for Warragamba Dam in Australia valued at USD14.5m.|
|Next Article:||NICE recommends MSD's Keytruda for bladder cancer.|